Situ cancer vaccine S astien Paris1, Agnes Pottier1, Laurent Levy1, Bo Lu2 1 Nanobiotix, Paris, Ile-de-France, France; 2Thomas Jefferson University, Philadelphia, PA, USA Correspondence: Agnes Pottier ([email protected]) Journal for ImmunoTherapy of Cancer 2016, four(Suppl 1):P358 Background Efficient immunotherapy requires optimal mixture of immunotherapeutic agents to build a robust immune response against cancer. In this framework, radiotherapy has verified its ability to induce immunogenic cell death (ICD), displaying a promising potential for effective mixture. Hafnium oxide (HfO2) nanoparticles, undergoing clinical trials for enhancing radiotherapy, was created as higher electron density material at the nanoscale to boost the absorption of PDGF-DD Proteins Recombinant Proteins radiation delivered inside tumors. The nanoparticles are taken up by cancer cells and, when exposed to radiotherapy, locally
Related Posts
